Human apolipoprotein E4 modulates the expression of Pin1, Sirtuin 1, and Presenilin 1 in brain regions of targeted replacement apoE mice

Neuroscience

Volumn 256, Issue , 2014, Pages 360-369

  Lattanzio, F ^a   Carboni, L ^a   Carretta, D ^a   Rimondini, R ^a   Candeletti, S ^a   Romualdi, P ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Alzheimer's disease; Apolipoprotein E; Brain derived Neurotrophic Factor; Pin1; Presenilin 1; Sirtuin 1

Indexed keywords

AMYLOID PRECURSOR PROTEIN; APOLIPOPROTEIN E3; APOLIPOPROTEIN E4; BRAIN DERIVED NEUROTROPHIC FACTOR; GAMMA SECRETASE; ISOPROTEIN; MESSENGER RNA; PEPTIDYLPROLYL ISOMERASE PIN1; PRESENILIN 1; SIRTUIN 1; NIMA-INTERACTING PEPTIDYLPROLYL ISOMERASE; PEPTIDYLPROLYL ISOMERASE;

ALLELE; ALZHEIMER DISEASE; AMNESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BRAIN REGION; CONTROLLED STUDY; DISEASE PREDISPOSITION; ENTORHINAL CORTEX; ENZYME ACTIVITY; FRONTAL CORTEX; GENE CONTROL; GENE EXPRESSION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENOTYPE; HIPPOCAMPUS; MALE; MEMORY DISORDER; MOLECULAR MECHANICS; MOUSE; NEUROFIBRILLARY TANGLE; NEUROMODULATION; NEUROPATHOLOGY; NEUROPROTECTION; NONHUMAN; PARIETAL CORTEX; PATHOPHYSIOLOGY; PIN1 GENE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROCESSING; PROTEIN SYNTHESIS REGULATION; PROTEIN TARGETING; PS1 GENE; SENILE PLAQUE; SIRT1 GENE; SPATIAL MEMORY; TRANSGENIC MOUSE; ANALYSIS OF VARIANCE; ANIMAL; BRAIN; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM;

ANALYSIS OF VARIANCE; ANIMALS; APOLIPOPROTEIN E4; BRAIN; GENE EXPRESSION REGULATION; HUMANS; MICE; MICE, TRANSGENIC; PEPTIDYLPROLYL ISOMERASE; PRESENILIN-1; RNA, MESSENGER; SIRTUIN 1;

EID: 84888386444     PISSN: 03064522     EISSN: 18737544     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2013.10.017     Document Type: Article

References (76)

1. Arancio O., Chao M.V. Neurotrophins, synaptic plasticity and dementia. Curr Opin Neurobiol 2007, 17:325-330.
2. Arosio B., Bulbarelli A., Bastias Candia S., Lonati E., Mastronardi L., Romualdi P., Candeletti S., Gussago C., Galimberti D., Scarpini E., Dell'Osso B., Altamura C., Maccarrone M., Bergamaschini L., D'Addario C., Mari D. Pin1 contribution to Alzheimer's disease: transcriptional and epigenetic mechanisms in patients with late-onset Alzheimer's disease. Neurodegener Dis 2012, 10:207-211.
3. Balastik M., Lim J., Pastorino L., Lu K.P. Pin1 in Alzheimer's disease: multiple substrates, one regulatory mechanism?. Biochim Biophys Acta 2007, 1772:422-429.
4. Bales K.R., Liu F., Wu S., Lin S., Koger D., DeLong C., Hansen J.C., Sullivan P.M., Paul S.M. Human APOE isoform-dependent effects on brain beta-amyloid levels in PDAPP transgenic mice. J Neurosci 2009, 29:6771-6779.
5. Ballard C., Gauthier S., Corbett A., Brayne C., Aarsland D., Jones E. Alzheimer's disease. Lancet 2011, 377:1019-1031.
6. Beffert U., Morfini G., Bock H.H., Reyna H., Brady S.T., Herz J. Reelin-mediated signaling locally regulates protein kinase B/Akt and glycogen synthase kinase 3beta. J Biol Chem 2002, 277:49958-49964.
7. Bonda D.J., Lee H.G., Camins A., Pallàs M., Casadesus G., Smith M.A., Zhu X. The sirtuin pathway in ageing and Alzheimer disease: mechanistic and therapeutic considerations. Lancet Neurol 2011, 10:275-279.
8. Bour A., Grootendorst J., Vogel E., Kelche C., Dodart J.C., Bales K., Moreau P.H., Sullivan P.M., Mathis C. Middle-aged human apoE4 targeted-replacement mice show retention deficits on a wide range of spatial memory tasks. Behav Brain Res 2008, 193:174-182.
9. Bu G. Apolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapy. Nat Rev Neurosci 2009, 10:333-344.
10. Buttini M., Yu G.Q., Shockley K., Huang Y., Jones B., Masliah E., Mallory M., Yeo T., Longo F.M., Mucke L. Modulation of Alzheimer-like synaptic and cholinergic deficits in transgenic mice by human apolipoprotein E depends on isoform, aging, and overexpression of amyloid beta peptides but not on plaque formation. J Neurosci 2002, 22:10539-10548.
11. Cacquevel M., Aeschbach L., Houacine J., Fraering P.C. Alzheimer's disease-linked mutations in presenilin-1 result in a drastic loss of activity in purified γ-secretase complexes. PLoS One 2012, 7:e35133.
12. Chen J., Zhou Y., Mueller-Steiner S., Chen L.F., Kwon H., Yi S., Mucke L., Gan L. SIRT1 protects against microglia-dependent amyloid-beta toxicity through inhibiting NF-kappaB signaling. J Biol Chem 2005, 280:40364-40374.
13. Chomczynski P., Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987, 162:156-159.
14. Clark R.A., Shoaib M., Hewitt K.N., Stanford S.C., Bate S.T. A comparison of InVivoStat with other statistical software packages for analysis of data generated from animal experiments. J Psychopharmacol 2012, 26:1136-1142.
15. Corder E.H., Saunders A.M., Strittmatter W.J., Schmechel D.E., Gaskell P.C., Small G.W., Roses A.D., Haines J.L., Pericak-Vance M.A. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993, 261:921-923.
16. Davidsson P., Bogdanovic N., Lannfelt L., Blennow K. Reduced expression of amyloid precursor protein, presenilin-1 and rab3a in cortical brain regions in Alzheimer's disease. Dement Geriatr Cogn Disord 2001, 12:243-250.
17. De Gasperi R., Sosa M.A., Dracheva S., Elder G.A. Presenilin-1 regulates induction of hypoxia inducible factor-1α: altered activation by a mutation associated with familial Alzheimer's disease. Mol Neurodegener 2010, 5:38.
18. De Strooper B., Saftig P., Craessaerts K., Vanderstichele H., Guhde G., Annaert W., Von Figura K., Van Leuven F. Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein. Nature 1998, 391:387-390.
19. Dickerson B.C., Sperling R.A. Large-scale functional brain network abnormalities in Alzheimer's disease: insights from functional neuroimaging. Behav Neurol 2009, 21:63-75.
20. Donmez G., Wang D., Cohen D.E., Guarente L. SIRT1 suppresses beta-amyloid production by activating the alpha-secretase gene ADAM10. Cell 2010, 142:320-332.
21. Dumanis S.B., Tesoriero J.A., Babus L.W., Nguyen M.T., Trotter J.H., Ladu M.J., Weeber E.J., Turner R.S., Xu B., Rebeck G.W., Hoe H.S. ApoE4 decreases spine density and dendritic complexity in cortical neurons in vivo. J Neurosci 2009, 29:15317-15322.
22. Ferri C.P., Prince M., Brayne C., Brodaty H., Fratiglioni L., Ganguli M., Hall K., Hasegawa K., Hendrie H., Huang Y., Jorm A., Mathers C., Menezes P.R., Rimmer E., Scazufca M., Alzheimer's Disease International Global prevalence of dementia: a Delphi consensus study. Lancet 2005, 366:2112-2117.
23. Finkel T., Deng C.X., Mostoslavsky R. Recent progress in the biology and physiology of sirtuins. Nature 2009, 460:587-591.
24. Fitz N.F., Cronican A.A., Saleem M., Fauq A.H., Chapman R., Lefterov I., Koldamova R. Abca1 deficiency affects Alzheimer's disease-like phenotype in human ApoE4 but not in ApoE3-targeted replacement mice. J Neurosci 2012, 32:13125-13136.
25. Fryer J.D., Simmons K., Parsadanian M., Bales K.R., Paul S.M., Sullivan P.M., Holtzman D.M. Human apolipoprotein E4 alters the amyloid-beta 40:42 ratio and promotes the formation of cerebral amyloid angiopathy in an amyloid precursor protein transgenic model. J Neurosci 2005, 25:2803-2810.
26. Fumagalli F., Racagni G., Riva M.A. The expanding role of BDNF: a therapeutic target for Alzheimer's disease?. Pharmacogenomics J 2006, 6:8-15.
27. Gao J., Wang W.Y., Mao Y.W., Gräff J., Guan J.S., Pan L., Mak G., Kim D., Su S.C., Tsai L.H. A novel pathway regulates memory and plasticity via SIRT1 and miR-134. Nature 2010, 466:1105-1109.
28. Grootendorst J., Bour A., Vogel E., Kelche C., Sullivan P.M., Dodart J.C., Bales K., Mathis C. Human apoE targeted replacement mouse lines: h-apoE4 and h-apoE3 mice differ on spatial memory performance and avoidance behavior. Behav Brain Res 2005, 159:1-14.
29. Harold D., et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet 2009, 41:1088-1093.
30. Hauser P.S., Narayanaswami V., Ryan R.O. Apolipoprotein E: from lipid transport to neurobiology. Prog Lipid Res 2011, 50:62-74.
31. Heyward F.D., Walton R.G., Carle M.S., Coleman M.A., Garvey W.T., Sweatt J.D. Adult mice maintained on a high-fat diet exhibit object location memory deficits and reduced hippocampal SIRT1 gene expression. Neurobiol Learn Mem 2012, 98:25-32.
32. Holtzman D.M., Bales K.R., Tenkova T., Fagan A.M., Parsadanian M., Sartorius L.J., Mackey B., Olney J., McKeel D., Wozniak D., Paul S.M. Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A 2000, 97:2892-2897.
33. Huang Y. Abeta-independent roles of apolipoprotein E4 in the pathogenesis of Alzheimer's disease. Trends Mol Med 2010, 16:287-294.
34. Hunter J.M., Cirrito J.R., Restivo J.L., Kinley R.D., Sullivan P.M., Holtzman D.M., Koger D., Delong C., Lin S., Zhao L., Liu F., Bales K., Paul S.M. Emergence of a seizure phenotype in aged apolipoprotein epsilon 4 targeted replacement mice. Brain Res 2012, 1467:120-132.
35. Jacobs H.I., Van Boxtel M.P., Jolles J., Verhey F.R., Uylings H.B. Parietal cortex matters in Alzheimer's disease: an overview of structural, functional and metabolic findings. Neurosci Biobehav Rev 2012, 36:297-309.
36. Jin K., LaFevre-Bernt M., Sun Y., Chen S., Gafni J., Crippen D., Logvinova A., Ross C.A., Greenberg D.A., Ellerby L.M. FGF-2 promotes neurogenesis and neuroprotection and prolongs survival in a transgenic mouse model of Huntington's disease. Proc Natl Acad Sci U S A 2005, 13:18189-18194.
37. Julien C., Tremblay C., Emond V., Lebbadi M., Salem N., Bennett D.A., Calon F. Sirtuin 1 reduction parallels the accumulation of tau in Alzheimer disease. J Neuropathol Exp Neurol 2009, 68:48-58.
38. Kim J., Basak J.M., Holtzman D.M. The role of apolipoprotein E in Alzheimer's disease. Neuron 2009, 63:287-303.
39. Kim J., Jiang H., Park S., Eltorai A.E., Stewart F.R., Yoon H., Basak J.M., Finn M.B., Holtzman D.M. Haploinsufficiency of human APOE reduces amyloid deposition in a mouse model of amyloid-β amyloidosis. J Neurosci 2011, 31:18007-18012.
40. Klein R.C., Mace B.E., Moore S.D., Sullivan P.M. Progressive loss of synaptic integrity in human apolipoprotein E4 targeted replacement mice and attenuation by apolipoprotein E2. Neuroscience 2010, 171:1265-1272.
41. Levi O., Jongen-Relo A.L., Feldon J., Roses A.D., Michaelson D.M. ApoE4 impairs hippocampal plasticity isoform-specifically and blocks the environmental stimulation of synaptogenesis and memory. Neurobiol Dis 2003, 13:273-282.
42. Li Y., Xu W., McBurney M.W., Longo V.D. SirT1 inhibition reduces IGF-I/IRS-2/Ras/ERK1/2 signaling and protects neurons. Cell Metab 2008, 8:38-48.
43. Liou Y.C., Sun A., Ryo A., Zhou X.Z., Yu Z.X., Huang H.K., Uchida T., Bronson R., Bing G., Li X., Hunter T., Lu K.P. Role of the prolyl isomerase Pin1 in protecting against age-dependent neurodegeneration. Nature 2003, 424:556-561.
44. Liou Y.C., Zhou X.Z., Lu K.P. Prolyl isomerase Pin1 as a molecular switch to determine the fate of phosphoproteins. Trends Biochem Sci 2011, 36:501-514.
45. Liu C.C., Kanekiyo T., Xu H., Bu G. Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat Rev Neurol 2013, 9:106-118.
46. Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001, 25:402-408.
47. Lu K.P., Zhou X.Z. The prolyl isomerase PIN1: a pivotal new twist in phosphorylation signalling and disease. Nat Rev Mol Cell Biol 2007, 8:904-916.
48. Lu P.J., Wulf G., Zhou X.Z., Davies P., Lu K.P. The prolyl isomerase Pin1 restores the function of Alzheimer-associated phosphorylated tau protein. Nature 1999, 399:784-788.
49. Maioli S., Puerta E., Merino-Serrais P., Fusari L., Gil-Bea F., Rimondini R., Cedazo-Minguez A. Combination of apolipoprotein E4 and high carbohydrate diet reduces hippocampal BDNF and arc levels and impairs memory in young mice. J Alzheimers Dis 2012, 32:341-355.
50. Michán S., Li Y., Chou M.M., Parrella E., Ge H., Long J.M., Allard J.S., Lewis K., Miller M., Xu W., Mervis R.F., Chen J., Guerin K.I., Smith L.E., McBurney M.W., Sinclair D.A., Baudry M., de Cabo R., Longo V.D. SIRT1 is essential for normal cognitive function and synaptic plasticity. J Neurosci 2010, 30:9695-9707.
51. Min S.W., Cho S.H., Zhou Y., Schroeder S., Haroutunian V., Seeley W.W., Huang E.J., Shen Y., Masliah E., Mukherjee C., Meyers D., Cole P.A., Ott M., Gan L. Acetylation of tau inhibits its degradation and contributes to tauopathy. Neuron 2010, 67:953-966.
52. Pastorino L., Sun A., Lu P.J., Zhou X.Z., Balastik M., Finn G., Wulf G., Lim J., Li S.H., Li X., Xia W., Nicholson L.K., Lu K.P. The prolyl isomerase Pin1 regulates amyloid precursor protein processing and amyloid-beta production. Nature 2006, 440:528-534.
53. Qin W., Yang T., Ho L., Zhao Z., Wang J., Chen L., Zhao W., Thiyagarajan M., MacGrogan D., Rodgers J.T., Puigserver P., Sadoshima J., Deng H., Pedrini S., Gandy S., Sauve A.A., Pasinetti G.M. Neuronal SIRT1 activation as a novel mechanism underlying the prevention of Alzheimer disease amyloid neuropathology by calorie restriction. J Biol Chem 2006, 281:21745-21754.
54. Reverte I., Klein A.B., Ratner C., Domingo J.L., Colomina M.T. Behavioral phenotype and BDNF differences related to apoE isoforms and sex in young transgenic mice. Exp Neurol 2012, 237:116-125.
55. Riddell D.R., Zhou H., Atchison K., Warwick H.K., Atkinson P.J., Jefferson J., Xu L., Aschmies S., Kirksey Y., Hu Y., Wagner E., Parratt A., Xu J., Li Z., Zaleska M.M., Jacobsen J.S., Pangalos M.N., Reinhart P.H. Impact of apolipoprotein E (ApoE) polymorphism on brain ApoE levels. J Neurosci 2008, 28:11445-11453.
56. Rodriguez G.A., Burns M.P., Weeber E.J., Rebeck G.W. Young APOE4 targeted replacement mice exhibit poor spatial learning and memory, with reduced dendritic spine density in the medial entorhinal cortex. Learn Mem 2013, 20:256-266.
57. Sasaki T., Maier B., Koclega K.D., Chruszcz M., Gluba W., Stukenberg P.T., Minor W., Scrable H. Phosphorylation regulates SIRT1 function. PLoS One 2008, 3:e4020.
58. Selkoe D.J. Alzheimer's disease. Cold Spring Harb Perspect Biol 2011, 3:a004457.
59. Shen L., Wang D.Q., Tso P., Jandacek R.J., Woods S.C., Liu M. Apolipoprotein E reduces food intake via PI3K/Akt signaling pathway in the hypothalamus. Physiol Behav 2011, 105:124-128.
60. Singh K., Chaturvedi R., Asim M., Barry D.P., Lewis N.D., Vitek M.P., Wilson K.T. The apolipoprotein E-mimetic peptide COG112 inhibits the inflammatory response to Citrobacter rodentium in colonic epithelial cells by preventing NF-kappaB activation. J Biol Chem 2008, 283:16752-16761.
61. Stanya K.J., Liu Y., Means A.R., Kao H.Y. Cdk2 and Pin1 negatively regulate the transcriptional corepressor SMRT. J Cell Biol 2008, 183:49-61.
62. Sullivan P.M., Han B., Liu F., Mace B.E., Ervin J.F., Wu S., Koger D., Paul S., Bales K.R. Reduced levels of human apoE4 protein in an animal model of cognitive impairment. Neurobiol Aging 2011, 32:791-801.
63. Sullivan P.M., Mezdour H., Aratani Y., Knouff C., Najib J., Reddick R.L., Quarfordt S.H., Maeda N. Targeted replacement of the mouse apolipoprotein E gene with the common human APOE3 allele enhances diet-induced hypercholesterolemia and atherosclerosis. J Biol Chem 1997, 272:17972-17980.
64. Sullivan P.M., Mace B.E., Maeda N., Schmechel D.E. Marked regional differences of brain human apolipoprotein E expression in targeted replacement mice. Neuroscience 2004, 124:725-733.
65. Tanzi R.E., Bertram L. Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective. Cell 2005, 120:545-555.
66. Tapia-Arancibia L., Aliaga E., Silhol M., Arancibia S. New insights into brain BDNF function in normal aging and Alzheimer disease. Brain Res Rev 2008, 59:201-220.
67. Trommer B.L., Shah C., Yun S.H., Gamkrelidze G., Pasternak E.S., Ye G.L., Sotak M., Sullivan P.M., Pasternak J.F., LaDu M.J. ApoE isoform affects LTP in human targeted replacement mice. Neuroreport 2004, 15:2655-2658.
68. Vance J.E., Hayashi H. Formation and function of apolipoprotein E-containing lipoproteins in the nervous system. Biochim Biophys Acta 2010, 1801:806-818.
69. Verghese P.B., Castellano J.M., Holtzman D.M. Apolipoprotein E in Alzheimer's disease and other neurological disorders. Lancet Neurol 2011, 10:241-252.
70. Wang C., Wilson W.A., Moore S.D., Mace B.E., Maeda N., Schmechel D.E., Sullivan P.M. Human apoE4-targeted replacement mice display synaptic deficits in the absence of neuropathology. Neurobiol Dis 2005, 18:390-398.
71. Wang S., Simon B.P., Bennett D.A., Schneider J.A., Malter J.S., Wang D.S. The significance of Pin1 in the development of Alzheimer's disease. J Alzheimers Dis 2007, 11:13-23.
72. Youmans K.L., Tai L.M., Nwabuisi-Heath E., Jungbauer L., Kanekiyo T., Gan M., Kim J., Eimer W.A., Estus S., Rebeck G.W., Weeber E.J., Bu G., Yu C., Ladu M.J. APOE4-specific changes in Aβ accumulation in a new transgenic mouse model of Alzheimer disease. J Biol Chem 2012, 287:41774-41786.
73. Yun S.H., Park K.A., Sullivan P., Pasternak J.F., Ladu M.J., Trommer B.L. Blockade of nicotinic acetylcholine receptors suppresses hippocampal long-term potentiation in wild-type but not ApoE4 targeted replacement mice. J Neurosci Res 2005, 82:771-777.
74. Zhang H., Wu L.M., Wu J. Cross-talk between apolipoprotein E and cytokines. Mediators Inflamm 2011, 2011:949072.
75. Zhang F., Kang Z., Li W., Xiao Z., Zhou X. Roles of brain-derived neurotrophic factor/tropomyosin-related kinase B (BDNF/TrkB) signalling in Alzheimer's disease. J Clin Neurosci 2012, 19:946-949.
76. Zhong N., Weisgraber K.H. Understanding the basis for the association of apoE4 with Alzheimer's disease: opening the door for therapeutic approaches. Curr Alzheimer Res 2009, 6:415-418.